Biocon

BIOCON

NSE

BSE

SectorHealthcare

Loading chart…

The Quarter story

The two most recent quarterly results, compared side-by-side.

Biocon maintains steady revenue growth and resilient core profits, though recent quarters show margin compression and softening demand in generics.

Consolidated revenue grows from ₹4,022 Cr to ₹4,391 Cr from Q1 FY26 to Q1 FY27, maintaining steady top-line scale.

Consolidated profit before tax margin falls from 7% to 3% from Q4 FY26 to Q1 FY27, indicating margin contraction.

Consolidated net profit before exceptional items rises from ₹31 Cr to ₹145 Cr from Q1 FY26 to Q1 FY27, showing resilient core earnings.

Generics revenue declines from ₹851 Cr to ₹760 Cr from Q3 FY26 to Q1 FY27, signaling demand softening.

Generics EBITDA margin recovers from 0% to 7% from Q1 FY26 to Q1 FY27, signaling healthy segment profitability.

Generics EBITDA dips from ₹75 Cr to ₹56 Cr from Q4 FY26 to Q1 FY27, reflecting a post-peak adjustment.

Biosimilars revenue expands from ₹2,458 Cr to ₹2,855 Cr from Q1 FY26 to Q1 FY27, driving consistent top-line growth.

Generics R&D margin drops from 11% to 6% from Q4 FY26 to Q1 FY27, showing reduced R&D intensity relative to sales.

Consolidated R&D spend as a percentage of revenue holds steady at 7% from Q1 FY26 to Q1 FY27, reflecting disciplined investment.

Consolidated profit before tax falls from ₹328 Cr to ₹141 Cr from Q4 FY26 to Q1 FY27, highlighting earnings normalization.

About the company

Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, and oncology treatments. The company operates manufacturing facilities in Bangalore, Hyderabad, and Visakhapatnam, utilizing various technology platforms such as microbial fermentation, chromatographic purification, chemical synthesis, and peptide synthesis. Biocon has expanded its global presence through strategic partnerships and has launched several biosimilar and generic products in international markets, including the United States, Europe, and emerging economies.

In the news